Elanco Animal Health (NYSE:ELAN) Hits New 52-Week High - What's Next?

Key Points

• Elanco Animal Health's stock reached a new 12-month high of $18.91 during mid-day trading, indicating strong investor interest and trading volume.
• Analysts have raised their price targets for the stock, with UBS Group setting a new target of $19.00 and Piper Sandler adjusting theirs to $18.00, reflecting positive sentiment among equity research analysts.
• Elanco reported earnings of $0.26 per share in its latest quarter, exceeding analyst expectations and showing a revenue increase of 4.8% year-over-year, which solidifies its financial position.

Shares of Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $18.91 and last traded at $18.74, with a volume of 1371449 shares traded. The stock had previously closed at $18.43.

Analyst Ratings Changes

Several equities research analysts have issued reports on ELAN shares. Zacks Research downgraded shares of Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 20th. Wall Street Zen upgraded shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Leerink Partners upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price objective for the company in a research report on Thursday, July 17th. William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. Finally, Leerink Partnrs upgraded shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $17.33.

Elanco Animal Health Trading Down 1.4%

The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40. The business's 50-day moving average price is $16.37 and its two-hundred day moving average price is $13.18. The company has a market capitalization of $9.20 billion, a price-to-earnings ratio of 21.53, a P/E/G ratio of 3.49 and a beta of 1.62.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. During the same period in the previous year, the business earned $0.30 earnings per share. The company's revenue was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Research analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Allworth Financial LP raised its position in Elanco Animal Health by 791.7% during the first quarter. Allworth Financial LP now owns 2,354 shares of the company's stock valued at $25,000 after purchasing an additional 2,090 shares in the last quarter. CoreCap Advisors LLC bought a new stake in shares of Elanco Animal Health during the fourth quarter worth $29,000. NBC Securities Inc. bought a new stake in shares of Elanco Animal Health during the first quarter worth $40,000. Parallel Advisors LLC grew its stake in shares of Elanco Animal Health by 92.2% during the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock worth $41,000 after buying an additional 1,852 shares during the last quarter. Finally, Versant Capital Management Inc grew its stake in shares of Elanco Animal Health by 65.9% during the first quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock worth $46,000 after buying an additional 1,740 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.